The Growing Threat to Patients

Every week, doctors, pharmacists, and families across America face a growing crisis: essential medications are becoming harder to find.

Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) are blocking access to essential medicines, controlling which manufacturers thrive and which ones fail. These powerful intermediaries have become gatekeepers of the market, making it harder for suppliers to expand and serve American patients.

The outcome? America opens medicine supply to unreliable sources, with more and more medications coming from China.

Proposed tariffs on Indian generics would only make this situation worse, raising costs and worsening shortages. Over 270 medicines are already in short supply across the U.S. today. Tariffs would drive up these numbers, impacting patients nationwide.

Medicine Security

The United States and India share a common goal: to ensure every patient has access to safe, affordable, and reliable medicine.

Together, through public–private partnerships and mutual trust, America and India can strengthen long-term access to essential generic medicines — not just by securing finished-dose supply, but also the critical inputs that power them: active pharmaceutical ingredients (APIs), key starting materials (KSMs), and drug intermediates (DIs).

By investing in strategic stockpiles and resilient manufacturing arrangements, both countries can proactively guard against future emergencies — from pandemics and hurricanes to geopolitical instability. This partnership reduces reliance on fragile supply chains and ensures a steady flow of the medicines Americans need most.

This is how we secure national medicine supply — by working with trusted allies to de-risk from China and build a more resilient future.

Reform the Market

PBMs and GPOs control nearly every dollar spent on generic drugs in the U.S. But their practices have made it nearly impossible for U.S. manufacturers to compete, while exposing the country to fragile foreign supply chains. Market reform can reduce monopolistic power and increase transparency, ensuring medicines remain affordable and accessible.

Adam is a U.S. Army veteran from Fort Benning, Georgia, with deployments to Iraq and Afghanistan. Now a logistics manager and father of three, he takes high blood pressure medication to treat his hypertension.

As a veteran managing a chronic condition, Adam depends on high-quality, affordable medicine made by U.S. allies, not risky alternatives from unreliable sources.

Margaret is a retired nurse and grandmother in rural North Carolina. She now volunteers at her local rural health clinic and helps manage prescription access for uninsured patients.

At the clinic where Margaret volunteers, tariffs on Indian generics could mean turning away patients who can no longer get the medicines they need.

John is a small business owner in Indiana who supplies components to the defense and transportation sectors. He takes pride in building durable products that keep America moving, whether it’s tanks or trucks.

John knows his workers keep America running and they rely on affordable, safe generics to stay healthy and on the job.